FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897790412> ?p ?o ?g. }

• W2897790412 endingPage "986" @default.
• W2897790412 startingPage "982" @default.
• W2897790412 abstract "Cells undergoing myelopoiesis in both bone marrow and the mature myeloid compartments in the blood represent a broad range of phenotypes in different stages of maturation and activation. Neoplasms that arise from this lineage are often heterogeneous and frequently display unique characteristics and outcomes depending on the originating subset or degree of differentiation 1, 2. This is particularly true for myeloid neoplasms (MN) which rely on multiple, separate flow cytometry panels for differential diagnosis 3, 4. While standard practice, this approach has inherent disadvantages which include the inability to observe co-expression patterns between markers contained in separate panels and increased time and labor associated with multiple flow cytometry assays. Use of a single, high-order panel that is able to differentiate multiple hematopoietic lineages, or distinguish different MNs would aid this effort and provide the opportunity to further characterize disease subsets. This panel was designed to detect cell surface markers associated with hematopoiesis with a special emphasis on the progression of myelopoiesis from hematopoietic progenitors. Because the study of hematopoietic disease requires a broad combination of early hematopoietic and mature myeloid markers 5, this panel is also appropriate for the general analysis of myelopoiesis, granulopoiesis, erythropoiesis, and megakaryocytopoiesis, in any human cell source that contains mature myeloid cells, myeloid progenitors, or hematopoietic progenitors (Table 1). Hematopoiesis is the process by which all types of blood cells arise from a common multipotent hematopoietic stem cell (HSC) identified by a lack of lineage-specific markers and by KIT (CD117) and CD34 co-expression6, 7. While more immature subsets of HSC can be identified using CD133 and CD38 8, 9, lineage−CD117+CD34+ cells encompass the most mature group of progenitor phenotypes that retain multipotent potential, and further differentiation of these cells proceeds down one of five hematopoietic lineages: erythropoiesis, lymphopoiesis, myelopoiesis, granulopoiesis, or megakaryocytopoiesis 10 (Fig. 1A). Once committed, progenitors of each lineage express cell surface markers that can be used to identify their increasingly restricted step-wise progression into mature phenotypes. Of these lineages, myelopoiesis is arguably the most complex regarding the diversity of fully differentiated phenotypes it can give rise to, and the numerous branch-points and subsets therein 11. Thus, flow cytometry analysis is a mainstay in the study of hematopoiesis, and in particular, myelopoiesis. Cancers that arise from the myeloid compartment are like-wise complex, retaining many of the surface markers reflective of their originating cell types, as well as acquiring aberrant expression of other myeloid markers or lineage types 1, 2. Immunophenotyping MNs is important for diagnosis, and in particular is critical to stratifying myeloid and lymphoid leukemia's, which are managed distinctly. MNs, including the myelodysplastic syndromes (MDS), are a heterogeneous group of diseases with increased risk of transformation to acute myeloid leukemia (AML), and poor survival rates 2. Assessment of MNs relies largely upon morphological assessment of bone marrow aspirate, and a series of lower-parameter flow cytometry panels run in parallel or succession 3, 4. Such panels were first outlined as a standardized set in 2008 by the International Workshop on Standardization of Flow Cytometry in MDS. An example screening would include 10 four-color panels, each of which include CD45, 7 of which would include the progenitor markers CD34 and/or CD117, 5 of which would include a combination of myeloid markers such as CD33, HLA-DR, CD13, CD36, CD64, and/or CD11b. The remaining parameters were occupied by lineage markers CD2, CD5, CD7, CD10, CD19, CD14, CD15, CD16, CD56, and/or CD71 such that each tube focuses on specific disease subsets 3. More recently, the EuroFlow Consortium has proposed a series of panels that would be run in a progressive manner beginning with one of several screening panels that is selected for based on clinical or laboratory indications. In regard to MNs, the results of this initial screening panel would orient each case toward one of three more comprehensive panel sets focusing on B cell precursors, acute lymphoblastic leukemia, or AML/MDS disease subsets using markers associated with B cells, T cells, or myeloid cells, respectively. Considering the AML/MDS panel set along with the initial screening panel, the EuroFlow Consortium recommendations encompass 36 markers for MNs cases 4. The panel presented here, includes a framework that allows a broad overview of myelopoiesis from HSC through mature monocyte/macrophage populations, myeloid-derived suppressor cells (MDSC), and a broad spectrum of MDS/MPN disease subtypes 2, 12-15 in a single 18-color panel (Table 2). The panel was constructed by first titrating the staining dilution of each antibody and calculating the optimal staining index (Supporting Information Figs. S1 and S2), and then in a step-wise manner building the panel based on category sets of parameters (Table 2), adding each category in turn (Supporting Information Fig. S3A–D). The panel includes as a utility anti-CD3 and anti-CD19 conjugated to brilliant violet® 510 (BV510), which can be excluded from analysis in the same detector as the viability marker Live/Dead™ Aqua (ThermoFisher Scientific), and anti-CD138 in order to gate out mature lymphocyte populations and plasma cells before analyzing hematopoietic populations. Similarly, erythropoietic and megakaryocytopoietic lineages can be separated from the myeloid lineages using CD71 and CD41a respectively, and committed progenitors therein can be identified using CD117, or a combination of CD45, CD34, and CD117. Within CD41a−CD71− cells, uncommitted HSC can be identified by gating on CD45+ or CD45low cells, followed by CD34+CD117+ cells, and then finally on CD33−HLA-DR− cells. Conversely, multipotent progenitors (MPP) and common myeloid progenitors (CMP) can be distinguished from committed monoblasts within the corresponding CD33+HLA-DR+ gate using CD64 expression. Common lymphoid progenitors (CLP) can be identified as CD34+CD117−11, although more mature lymphocyte populations are removed from analysis using CD3 and CD19 as part of a common “dump gate” along with the viability marker. More mature monocytic and granulocytic populations can be analyzed within the CD34− gate. Here, mature monocytes can be identified by CD14 expression, whereas promonocytes can be identified as CD33+CD64+HLA-DR+ and CD11c+ after gating on CD117− cells. The hierarchy of granulocyte maturation can be analyzed by first gating on CD33−CD64− cells within the CD117− gate, and then by increasing CD16 expression on CD11blow cells. Finally, fully mature neutrophils can be distinguished from band cells using SSC and CD45 expression (Fig. 1B, Supporting Information Table S3). Importantly, the samples stained here were processed by density gradient centrifugation to obtain bone marrow mononuclear cells (BMMNC), as many patient bone marrow biopsies are done. While standard practice, this methodology excludes polymorphonuclear cells, such as mature neutrophils. Alternative sample processing, such as RBC lysis can retain these populations if desired (Supporting Information Fig. S4). In addition to classifying normal hematopoietic lineages, CD15, CD41a, and CD71 are key markers that can differentiate between several types of MNs that in combination with CD32 and CD163 can, in theory, distinguish between the majority of MDS subtypes, and further sub-fractionate disease subsets including CMML (Fig. 1C, and Supporting Information Figs. S6–S8) 16-22. While the basic design of this panel focuses on myeloid lineages, the inclusion of CD38 and CD45RA in place of disease differentiating markers, such as CD32 or CD163, could aid in the analysis of long-term HSC and HSC subtypes 11. With high-order cytometry, algorithm-guided analyses offer a more comprehensive and objective analytic option compared with conventional gate-based approaches which require foreknowledge of cellular phenotypes. Here, we used spanning-tree progression analysis of density-normalized events (SPADE) to assign cells to 1 of 200 distinct nodes based on the expression of each parameter (with the exception of the viability/dump, forward scatter, and side scatter parameters) and to then cluster these nodes using a previously described hierarchical algorithm 23. This resulted in 37 distinct node clusters, or phenotypes (Supporting Information Figs. S9 and S10, Supporting Information Table S4). Thirty of these phenotypes correspond to populations identified by gate-based analysis, and in many cases identified further sub-populations, as annotated by a numeric suffix (Supporting Information Figs. S4 and S10). SPADE also identified seven phenotypes that do not correspond to populations identified by the gate based analysis. While not demonstrated here, this panel is suitable for other algorithm-guided analysis in addition to SPADE including t-SNE/viSNE, Wanderlust, FlowSOM, or PhenoGraph 24-26. In summation, this optimized panel is suitable for the study of hematopoiesis with an emphasis on myelopoiesis. Because this panel is able to distinguish phenotypes across a broad range of the myeloid compartment, it can characterize numerous MPNs and in theory differentiate a large portion of MDS subtypes, including CMML. It also has the potential to aid the study of MPNs by further stratifying disease subsets or defining novel biomarker combinations therein, particularly when combined with algorithm-guided analyses such as SPADE. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W2897790412 created "2018-10-26" @default.
• W2897790412 creator A5003759306 @default.
• W2897790412 creator A5004554374 @default.
• W2897790412 creator A5036699887 @default.
• W2897790412 creator A5041754278 @default.
• W2897790412 creator A5064581434 @default.
• W2897790412 date "2018-10-01" @default.
• W2897790412 modified "2023-10-17" @default.
• W2897790412 title "OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms" @default.
• W2897790412 cites W1588840730 @default.
• W2897790412 cites W1810935231 @default.
• W2897790412 cites W1918028620 @default.
• W2897790412 cites W1963578712 @default.
• W2897790412 cites W1982202983 @default.
• W2897790412 cites W2010847848 @default.
• W2897790412 cites W2013169247 @default.
• W2897790412 cites W2073256527 @default.
• W2897790412 cites W2082462757 @default.
• W2897790412 cites W2090384198 @default.
• W2897790412 cites W2090630520 @default.
• W2897790412 cites W2095664313 @default.
• W2897790412 cites W2107551122 @default.
• W2897790412 cites W2124014290 @default.
• W2897790412 cites W2125458360 @default.
• W2897790412 cites W2134525239 @default.
• W2897790412 cites W2166355785 @default.
• W2897790412 cites W2181027469 @default.
• W2897790412 cites W2460490710 @default.
• W2897790412 cites W2461073387 @default.
• W2897790412 cites W2461710372 @default.
• W2897790412 cites W2614976199 @default.
• W2897790412 cites W2738042624 @default.
• W2897790412 cites W2769394326 @default.
• W2897790412 cites W4211259900 @default.
• W2897790412 doi "https://doi.org/10.1002/cyto.a.23598" @default.
• W2897790412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6484443" @default.
• W2897790412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30347519" @default.
• W2897790412 hasPublicationYear "2018" @default.
• W2897790412 type Work @default.
• W2897790412 sameAs 2897790412 @default.
• W2897790412 citedByCount "2" @default.
• W2897790412 countsByYear W28977904122021 @default.
• W2897790412 countsByYear W28977904122022 @default.
• W2897790412 crossrefType "journal-article" @default.
• W2897790412 hasAuthorship W2897790412A5003759306 @default.
• W2897790412 hasAuthorship W2897790412A5004554374 @default.
• W2897790412 hasAuthorship W2897790412A5036699887 @default.
• W2897790412 hasAuthorship W2897790412A5041754278 @default.
• W2897790412 hasAuthorship W2897790412A5064581434 @default.
• W2897790412 hasBestOaLocation W28977904121 @default.
• W2897790412 hasConcept C109159458 @default.
• W2897790412 hasConcept C203014093 @default.
• W2897790412 hasConcept C2779282312 @default.
• W2897790412 hasConcept C28328180 @default.
• W2897790412 hasConcept C2994430510 @default.
• W2897790412 hasConcept C54355233 @default.
• W2897790412 hasConcept C70721500 @default.
• W2897790412 hasConcept C71924100 @default.
• W2897790412 hasConcept C86803240 @default.
• W2897790412 hasConcept C95862172 @default.
• W2897790412 hasConceptScore W2897790412C109159458 @default.
• W2897790412 hasConceptScore W2897790412C203014093 @default.
• W2897790412 hasConceptScore W2897790412C2779282312 @default.
• W2897790412 hasConceptScore W2897790412C28328180 @default.
• W2897790412 hasConceptScore W2897790412C2994430510 @default.
• W2897790412 hasConceptScore W2897790412C54355233 @default.
• W2897790412 hasConceptScore W2897790412C70721500 @default.
• W2897790412 hasConceptScore W2897790412C71924100 @default.
• W2897790412 hasConceptScore W2897790412C86803240 @default.
• W2897790412 hasConceptScore W2897790412C95862172 @default.
• W2897790412 hasFunder F4320306536 @default.
• W2897790412 hasFunder F4320308854 @default.
• W2897790412 hasFunder F4320337351 @default.
• W2897790412 hasIssue "10" @default.
• W2897790412 hasLocation W28977904121 @default.
• W2897790412 hasLocation W28977904122 @default.
• W2897790412 hasLocation W28977904123 @default.
• W2897790412 hasLocation W28977904124 @default.
• W2897790412 hasOpenAccess W2897790412 @default.
• W2897790412 hasPrimaryLocation W28977904121 @default.
• W2897790412 hasRelatedWork W2023388424 @default.
• W2897790412 hasRelatedWork W2050361995 @default.
• W2897790412 hasRelatedWork W2263407240 @default.
• W2897790412 hasRelatedWork W2413629122 @default.
• W2897790412 hasRelatedWork W2469312050 @default.
• W2897790412 hasRelatedWork W2475273306 @default.
• W2897790412 hasRelatedWork W2897790412 @default.
• W2897790412 hasRelatedWork W3000252975 @default.
• W2897790412 hasRelatedWork W4245859490 @default.
• W2897790412 hasRelatedWork W618769782 @default.
• W2897790412 hasVolume "93" @default.
• W2897790412 isParatext "false" @default.
• W2897790412 isRetracted "false" @default.
• W2897790412 magId "2897790412" @default.
• W2897790412 workType "article" @default.